THIS MONTH’S ISSUE

Read, save, and print articles from the current issue

ARTICLES

Chronological index
2013–2018

PRODUCT GUIDES

Compare all instruments
and software systems

DEPARTMENTS

Chronological index
2013–2018

WEBINARS

Register Now and
On Demand

Home » Top news

Bio-Techne buys Exosome Diagnostics

July 2, 2018Bio-Techne Corp. will acquire Exosome Diagnostics for $250 million in cash plus contingent consideration of up to $325 million due upon the achievement of certain future milestones. The deal is expected to close by early August.

The purchase includes ExoDx Prostate(IntelliScore), a urine-based test to assist physicians in determining the need for a prostate biopsy in patients with an ambiguous PSA test result. Exosome Dx has approximately 200 filed patents and applications to protect the technology and enable the development of novel, highly sensitive diagnostics in various pathologies with either difficult or no current diagnostic solutions, such as prostate, bladder, kidney, breast, and glioblastoma.

“The noninvasive nature of this technology creates a new process for liquid biopsies and is likely to transform medical practice,” Charles R. Kummeth, president and CEO of Bio-Techne, said in a press release.

This is Bio-Techne’s 14th acquisition in the past five years.

More top news

Print Friendly, PDF & Email
Tags: ,

X